Health In Tech Inc

Aktienanalyse zu Health In Tech Inc (HIT)

$0.968

+0.008 (+0.83%)Zum Schluss

Loading chart…
High
0.963
Open
0.961
VWAP
0.96
Vol
37.30K
Mkt Cap
Low
0.956
Amount
35.90K
EV/EBITDA, TTM
-1.99

Health In Tech, Inc. is an AI-enabled insurance technology platform company. The Company offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. It offers a marketplace designed to create healthcare plan solutions while streamlining processes through vertical integration, process simplification, and automation. Its services are delivered through three subsidiaries: Stone Mountain Risk, LLC (SMR), International Captive Exchange, LLC (ICE), and HI Card LLC’s HI Card platform (HI Card). The SMR is a program manager specializing in customized self-funded programs for small businesses. ICE is a managing general underwriter. ICE assists with underwriting activities through its Web-based SaaS quoting platform, Enhance Do It Yourself Benefit System (eDIYBS). HI Card seeks to simplify healthcare management with a single standardized transaction and service platform.

AI analysis of Health In Tech Inc (HIT)

hold

Health In Tech, Inc. is currently not a good buy due to its declining revenue and negative earnings, despite a potential upside indicated by analyst targets. The current price is $0.98, with a forward P/E of 136.99, suggesting high expectations for future earnings. However, the company has reported a significant year-to-date decline of 44% and a one-year change of -65.97%, indicating ongoing financial struggles. The main risk is the recent revenue decline of 13.5% year-over-year, which raises concerns about its short-term performance.

Bewertungskennzahlen

The current forward P/E ratio for Health In Tech Inc (HIT) is 136.99, compared to its 5-year average forward P/E of 67.73.

Forward P/E

Overvalued
5Y Average P/E
67.73
Current P/E
136.99
Überbewertet
123.63
Unterbewertet
11.82

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
6.90
Current EV/EBITDA
-1.99
Überbewertet
19.37
Unterbewertet
-5.57

Forward P/S

Fair
5Y Average P/S
1.67
Current P/S
0.90
Überbewertet
3.00
Unterbewertet
0.35

Event-Zeitleiste

2026-08-13 (ET)

17:00:00

Health In Tech Sees 2026 Revenue of $45M-$50M

17:00:00

Company Reports Q2 Revenue of $8.1MM, Exceeding Expectations

2026-06-11 (ET)

12:30:00

Health In Tech Files $300M Mixed Securities Shelf

2026-05-13 (ET)

16:10:00

Health In Tech Reiterates 2026 Revenue Guidance of $45M to $50M

16:10:00

Health In Tech Reports Q1 Revenue of $8.8M, Beating Expectations

News

HIT FAQ — answered by Alphio AI

Health In Tech, Inc. is an AI-enabled insurance technology platform company. The Company offers a marketplace that improves processes in the healthcare industry through vertical integration, process simplification, and automation. It offers a marketplace designed to create healthcare plan solutions while streamlining processes through vertical integration, process simplification, and automation. Its services are delivered through three subsidiaries: Stone Mountain Risk, LLC (SMR), International Captive Exchange, LLC (ICE), and HI Card LLC’s HI Card platform (HI Card). The SMR is a program manager specializing in customized self-funded programs for small businesses. ICE is a managing general underwriter. ICE assists with underwriting activities through its Web-based SaaS quoting platform, Enhance Do It Yourself Benefit System (eDIYBS). HI Card seeks to simplify healthcare management with a single standardized transaction and service platform. It operates in the Financials sector.

Health In Tech, Inc. is currently not a good buy due to its declining revenue and negative earnings, despite a potential upside indicated by analyst targets. The current price is $0.98, with a forward P/E of 136.99, suggesting high expectations for future earnings. However, the company has reported a significant year-to-date decline of 44% and a one-year change of -65.97%, indicating ongoing financial struggles. The main risk is the recent revenue decline of 13.5% year-over-year, which raises concerns about its short-term performance.

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Kostenlos starten